Navigation Links
More Evidence That Caffeine Can Jolt Memory
Date:7/6/2009

High doses may protect against Alzheimer's symptoms, study in mice suggests

SUNDAY, July 5 (HealthDay News) -- The growing evidence that caffeine consumption may help treat or prevent Alzheimer's disease has received an extra boost from two new studies.

Florida researchers report that a daily dose of 500 milligrams of caffeine -- the equivalent found in five 8-ounce cups of coffee -- reversed memory issues in mice bred to develop Alzheimer-like symptoms. After two months on the stimulant, the mice rebounded to score just as well on memory tests as normal mice of the same age that had never exhibited signs of dementia.

The studies, published in the July 5 online edition of the Journal of Alzheimer's Disease, also found that caffeine cut by half the mice's excessive blood and brain levels of beta amyloid, the protein linked to characteristic plaque found in human Alzheimer's disease.

"The new findings provide evidence that caffeine could be a viable 'treatment' for established Alzheimer's disease, and not simply a protective strategy," lead author Gary Arendash, a University of South Florida neuroscientist, said in a news release. "That's important because caffeine is a safe drug for most people, it easily enters the brain, and it appears to directly affect the disease process."

Past work at the Florida Alzheimer's Disease Research Center in Tampa, where these studies were done, found that caffeine in early adulthood appeared to prevent memory problems from occurring in these specially bred mice, possibly because of the stimulant's ability to calm the brain inflammation that causes beta amyloid levels to rise.

The research center also previously found that caffeine reduces beta amyloid levels in elderly people without dementia just as quickly as it does in the mice bred to have Alzheimer's symptoms.

Studies to test whether caffeine can help people with mild cognitive impairment or early Alzheimer's disease are likely to follow, investigator Huntington Potter, director of the Florida Alzheimer's Disease Research Center, said in the news release.

While consuming 500 milligrams of caffeine a day would not cause ill effects for most people, Arendash noted that people with high blood pressure or who are pregnant need to limit their caffeine intake. It is not known whether a smaller daily dose of caffeine would produce the same beneficial effects on the Alzheimer's mice.

In the most recent experiments, the researchers also found that caffeine did not improve the memory of normal mice as it did for the Alzheimer's mice. "This suggests that caffeine will not increase memory performance above normal levels. Rather, it appears to benefit those destined to develop Alzheimer's disease," Arendash said.

More information

The Alzheimer's Association has more about Alzheimer's disease.



-- Kevin McKeever



SOURCE: University of South Florida, news release, July 5, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community
2. New Scientific Evidence Suggests Humans Resistant to Phthalate Effect on Lab Rodents
3. American Dental Association, The Forsyth Institute Collaborate to Pilot Evidence-Based Dentistry Training Course
4. MEDRAD Introduces Manage.Report - Advances Evidence-Based Decision Making
5. Evidence-Based Analysis of Aspartame Research
6. CPM Resource Center and The Shams Group Partner to Help Hospitals Integrate Evidence-Based Clinical Content Into Information Systems
7. Decision by Medicares CMS to Deny Coverage for Virtual Colon Cancer Tests Underscores Lack of Evidence on Cancer Prevention
8. More evidence for the benefit of exercise in cardiovascular disease -- and even in heart failure
9. New Evidence Supports Efficacy and Value of Smith & Nephew NPWT Products
10. Wound Management Technologies, Inc. Announces the Presentation of Evidence Based Clinical Studies at the Symposium on Advanced Wound Care Conference in Dallas
11. First evidence for DNA-based vaccination against chronic hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
More Evidence That Caffeine Can Jolt Memory
(Date:5/26/2017)... ... 26, 2017 , ... Leading CEOs from biotech, pharmaceutical, and ... 31st at The Four Seasons Hotel Boston. , The Boston CEO Conference ... exclusive access to key decision makers who influence deal making and investment. Attendees ...
(Date:5/26/2017)... , ... May 26, 2017 , ... Amir Qureshi, MD ... a powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita SCS System has ... are pleased to be the first in Arkansas to introduce the most powerful SCS ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of ... the healthiest seniors are located in the Midwest. With the average cost of healthcare ... people are concerned with both the quality and affordability of where they live. An ...
(Date:5/26/2017)... ... May 26, 2017 , ... via seating is proud to ... task chair specifically designed for clinical areas. Genie Copper Mesh is a crossover ... Cupron® to provide customers with a game changing chair that is affordably priced,” ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... After raising ... Antzy Top gadget will continue to be available at a discounted crowdfunding price on ... with stress wherever they are, I also wanted to bring a fidget toy to ...
Breaking Medicine News(10 mins):
(Date:5/23/2017)... , May 23, 2017  Leaf Healthcare, ... innovative medical devices for pressure ulcer prevention, will ... American Association of Critical Care Nurses, National Teaching ... 22-25. The Leaf Patient Monitoring System ... for the hospital environment.  The system seamlessly tracks ...
(Date:5/18/2017)... 18, 2017  Two Bayer U.S. Pharmaceutical leaders received ... its recent 28 th Woman of the ... showcases HBA,s longstanding mission of furthering the advancement and ... Cindy Powell-Steffen , senior director of brand ... and Libby Howe , a regional business manager ...
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based in ... Parkinson,s disease (PD), has enrolled the first patient in the ... multicenter study involving patients with PD and taking place at ... 9-to-12-month period. The first stage is open label and involves ... include Denver , Boca Raton ...
Breaking Medicine Technology: